Cassava Sciences (SAVA) has entered into an agreement with Yale University for a license to intellectual property rights, including an exclusive license to an issued US method of treatment patent for simufilam as a potential treatment for seizures related to rare neurodevelopmental disorders including tuberous sclerosis complex. Simufilam is Cassava’s proprietary small molecule drug candidate that targets filamin A.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAVA: